Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia

JAMA

Volumn 298, Issue 16, 2007, Pages 1888-1899

  Bolton Moore, Carolyn ^a   Mubiana Mbewe, Mwangelwa ^a   Cantrell, Ronald A ^a,b   Chintu, Namwinga ^a   Stringer, Elizabeth M ^a,b   Chi, Benjamin H ^a,b   Sinkala, Moses ^b,d   Kankasa, Chipepo ^a,c   Wilson, Craig M ^b   Wilfert, Catherine M ^e   Mwango, Albert ^d   Levy, Jens ^a   Abrams, Elaine J ^f   Bulterys, Marc ^g   Stringer, Jeffrey S A ^a,b  

^a CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

^d MINISTRY OF HEALTH   (Zambia)

^e ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^f Columbia University College of Physicians and Surgeons ^*  (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD HEALTH CARE; CHILDHOOD MORTALITY; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PRIORITY JOURNAL; WEIGHT GAIN; ZAMBIA; COMMUNITY CARE; GOVERNMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; MORTALITY; PRESCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COMMUNITY HEALTH SERVICES; FEMALE; GOVERNMENT PROGRAMS; HIV INFECTIONS; HUMANS; INFANT; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WEIGHT GAIN; ZAMBIA;

EID: 35448950466     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.16.1888     Document Type: Article

References (47)

1. UNAIDS. Report on the Global AIDS Epidemic. Geneva, Switzerland: World Health Organization; 2006.
2. World Health Organization. Taking Stock: HIV in Children. Geneva, Switzerland: World Health Organization; 2005.
3. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364(9441):1236-1243.
4. Stringer EM, Sinkala M, Stringer JS, et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS. 2003;17(9):1377-1382.
5. United Nations Children's Fund. Country profile: Zambia. http://www.unicef.org/infobycountry/zambia_statistics.html#25. Accessed February 4, 2007.
6. US President's Emergency Plan for AIDS Relief. Country profile: Zambia. http://www.pepfar.gov/press/75974.htm. Accessed January 11, 2007.
7. Global Fund to Fight AIDS, Tuberculosis and Malaria. Zambia and the Global Fund: portfolio of grants. http://www.theglobalfund.org/Programs/ Portfolio.aspx?countryID=ZAM&lang=. Accessed January 11, 2007.
8. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296(7):782-793.
9. Kober K, Van Damme W. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet. 2004;364(9428):103-107.
10. World Health Organization. Joint WHO/PEPFAR meeting on task shifting; June 14, 2007; Kigali, Rwanda. http://www.who.int/entity/hiv/mediacentre/ kigali_07/en/index/html. Accessibility verified October 4, 2007.
11. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access. Geneva, Switzerland: World Health Organization; 2006.
12. World Health Organization. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003 Revision. Geneva, Switzerland: World Health Organization; 2004.
13. Zambian National AIDS Council. National Guidelines for Management and Care of Patients With HIV/AIDS. Lusaka, Zambia: Printech Press; 2004.
14. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height, and Body Mass Index-for-Age: Methods and Development. Geneva, Switzerland: WHO Press; 2006.
15. Centers for Disease Control and Prevention. A SAS program for CDC growth charts. http://www.cdc.gov/nccdphp/dnpa/growthcharts/sas.htm. Accessed February 7, 2007.
16. World Health Organization. Cotrimoxazole Prophylaxis for HIV-Related Infections Among Children, Adolescents, and Adults. Geneva, Switzerland: WHO Press; 2006.
17. Fusco H, Hubschman T, Mweeta V, et al. Electronic patient tracking supports rapid expansion of HIV care and treatment in resource-constrained settings [abstract MoPe11.2C37]. Paper presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
18. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051-1058.
19. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84.
20. Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194(8):1108-1114.
21. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Institute; 1995.
22. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80(3):557-572.
23. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20(18):2355-2360.
24. World Health Organization. Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance. Geneva, Switzerland: World Health Organization; 2005.
25. Protection of Human Subjects, 45 CFR pt 46 (2005). http://www.hhs.gov/ ohrp/humansubjects/guidance/45cfr46.htm. Accessed February 5, 2007.
26. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817-824.
27. Barry G, Coovadia A, Marais B, Malan E, Moultrie H. Analysis of HIV-infected infants under 1 year starting antiretroviral treatment at Coronation Paediatric HIV Clinic in Coronationville, Johannesburg [abstract MoPe0233]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada.
28. Anabwani GM, Lowenthal E, Marape M, et al. Long term response to highly active antiretroviral therapy among treatment naive children in Botswana [abstract MoPe0261]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada.
29. Olson D, Sauvageot D, Ferradini L, Humblet P. Antiretroviral therapy (ART) outcomes in children <13 years of age in resource-poor countries (RPCs): a medecins sans frontieres (MSF) cohort [abstract MoAb0204]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada.
30. Bobat R, Coovadia H, Moodley D, Coutsoudis A, Gouws E. Growth in early childhood in a cohort of children born to HIV-1-infected women from Durban, South Africa. Ann Trop Paediatr. 2001;21(3):203-210.
31. Berhane R, Bagenda D, Marum L, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics. 1997;100(1):E7.
32. Laufer MK, van Oosterhout JJ, Perez MA, et al. Observational cohort study of HIV-infected African children. Pediatr Infect Dis J. 2006;25(7):623-627.
33. George E, Noel F, Bois G, et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis. 2007;195(10):1411-1418.
34. Kuhn L, Kasonde P, Sinkala M, et al. Prolonged breast-feeding and mortality up to two years post-partum among HIV-positive women in Zambia. AIDS. 2005;19(15):1677-1681.
35. De Baets AJ, Bulterys M, Abrams EJ, Kankassa C, Pazvakavambwa IE. Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level. Pediatr Infect Dis J. 2007;26(2):163-173.
36. Mwinga A. Challenges and hope for the diagnosis of tuberculosis in infants and young children. Lancet. 2005;365(9454):97-98.
37. Kaminsa-Kabanje S, Jham M, Kancheya N, Jurkuvenas V, Kimerling M, Reid S. Integration of tuberculosis (TB) and HIV care in primary health care services in Lusaka, Zambia [abstract MoPe0168]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada.
38. Kankasa C, Katepa-Bwalya M, Katuta R, et al. Routine and universal counseling and testing among hospitalized children at University Teaching Hospital, Lusaka, Zambia [abstract 683]. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
39. Aledort JE, Ronald A, Le Blancq SM, et al. Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature. 2006;444(7115)(suppl 1):19-28.
40. Ginsburg AS, Miller A, Wilfert CM. Diagnosis of pediatric human immunodeficiency virus infection in resource-constrained settings. Pediatr Infect Dis J. 2006;25(11):1057-1064.
41. Bobat R, Moodley D, Coutsoudis A, Coovadia H, Gouws E. The early natural history of vertically transmitted HIV-1 infection in African children from Durban, South Africa. Ann Trop Paediatr. 1998;18(3):187-196.
42. Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) study [late breaker WESS103]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia.
43. World Health Organization. The 3 by 5 Initiative: AIDS treatment for children. http://www.who.int/3by5/paediatric/en/index.html. Accessed February 7, 2007.
44. Dumas S, Chi B, Mubiana-Mbewe M, Bolton C. Barriers to providing antiretroviral therapy (ART) to HIV-infected children in Lusaka, Zambia [abstract MoPE0234]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, ON, Canada.
45. Kline MW. Perspectives on the pediatric HIV/AIDS pandemic: catalyzing access of children to care and treatment. Pediatrics. 2006;117(4):1388-1393.
46. McConnell MS, Byers RH, Frederick T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr. 2005;38(4):488-494.
47. Rosenblatt HM, Stanley KE, Song LY, et al. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis. 2005;192(3):445-455.